No Data
The actual controller of Qingdao Haier Biomedical Co., Ltd. (688139.SH) and parties acting in concert have increased their shareholding by 0.3868 million shares, with a plan to increase the total shareholding by no more than 2%.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that the company's actual controller, Haier Group Corporation, has a concerted party, Qingdao...
Qingdao Haier Biomedical Co., Ltd. (688139.SH): has actually repurchased 0.53% of the company's shares.
Gelonghui reported on January 8 that Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that on January 7, 2025, the company completed its share buyback, having repurchased a total of 1,691,244 shares, accounting for 0.53% of the company's total equity. The highest share buyback price was 33.01 yuan/share, the lowest was 24.64 yuan/share, and the average buyback price was 29.54 yuan/share, with a total amount of funds used being 49.9644 million yuan (excluding transaction fees).
Qingdao Haier BiomedicalLtd (SHSE:688139) Sheds CN¥1.2b, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Haier Biomedical Plans Up to 200 Million Yuan Share Buyback
Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.
A specific plan recognized by all relevant parties could not be formed.
Qingdao Haier Biomedical Nixes Plan to Absorb Shanghai RAAS; Shares Fall 11%
Market Still Lacking Some Conviction On Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)
